Agent for preventing or treating small intestinal injury induced by specific NSAID and PPI
Inventors
Oikawa, Yosuke • Tanaka, Yoshiki • Ohno, Hiroshi • Shimakawa, Masaki
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11219650-B2
Publication Date
2022-01-11
Expiration Date
Abstract
An object of the present invention is to provide an agent for preventing or treating small intestinal injury induced by an NSAID with a half-life of less than 14 hours and a proton pump inhibitor. The present invention provides an agent for preventing or treating small intestinal injury induced by a non-steroidal anti-inflammatory drug with a half-life of less than 14 hours and a proton pump inhibitor, and an agent for preventing or treating a fat-associated disease and/or inflammation accompanying the small intestinal injury, the agents comprising a Bifidobacterium bacterium or a processed product thereof.
Core Innovation
The invention relates to an agent based on Bifidobacterium bifidum G9-1 and processed products thereof for preventing or treating small intestinal injury induced by a non-steroidal anti-inflammatory drug (NSAID) with a half-life of less than 14 hours in combination with a proton pump inhibitor (PPI). The method is applicable to a human or a non-human animal in need thereof.
The invention further provides treatment for a fat-associated disease and/or inflammation accompanying small intestinal injury induced by the NSAID/PPI combination. Documented examples include NAFLD/NASH accompanied by endotoxin-mediated permeability, and the approach is based on administering Bifidobacterium bifidum G9-1 or a processed product thereof.
The processed product is one or more selected from a disrupted bacterial cell suspension, culture medium or culture supernatant of the bacterial cells, solid residues separated by solid-liquid separation, dead cells, and acetic acid. The disclosure reports that Bifidobacterium reduces hematocrit reduction, intestinal permeability increases, and villi loss associated with NSAID/PPI administration, and that dead bacteria and acetic acid can also inhibit permeability increase.
Claims Coverage
The independent claims cover methods for preventing or treating small intestinal injury induced by an NSAID with a half-life of less than 14 hours together with a proton pump inhibitor, and also preventing or treating fat-associated disease and/or inflammation accompanying such injury. The claim defines at least three main inventive elements: administration of Bifidobacterium bifidum G9-1 (or specified processed products), limitation to the NSAID/PPI injury context, and timing of administration starting on the same day.
Administering Bifidobacterium bifidum G9-1 or processed product
A method comprising administering Bifidobacterium bifidum G9-1 or a processed product thereof to a human or a non-human animal in need thereof.
Treating NSAID/PPI-induced small intestinal injury with half-life less than 14 hours
Preventing or treating small intestinal injury induced by a non-steroidal anti-inflammatory drug with a half-life of less than 14 hours and a proton pump inhibitor.
Processed products include disrupted cells, dead cells, and acetic acid
The processed product thereof is one or more selected from a disrupted bacterial cell suspension, culture medium or culture supernatant of the bacterial cells, solid residues separated from such disrupted cell suspension, culture medium or culture supernatant, dead cells of the bacteria, and acetic acid.
Starting administration on the same day as the NSAID/PPI
The administration of the bacteria is started on the same day as administration of the non-steroidal anti-inflammatory drug.
Overall, the independent claim family centers on preventing or treating NSAID (half-life <14 hours) plus PPI-induced small intestinal injury by administering Bifidobacterium bifidum G9-1 or processed products including disrupted cells, dead cells, and acetic acid, with administration started on the same day.
Stated Advantages
Prevents or treats small intestinal injury induced by a non-steroidal anti-inflammatory drug with a half-life of less than 14 hours and a proton pump inhibitor.
Prevents or treats fat-associated disease and/or inflammation accompanying small intestinal injury induced by the NSAID and proton pump inhibitor.
Reduces NSAID/PPI-induced intestinal permeability increase and reduces villi loss, as supported by experimental evidence in rodents.
Can inhibit intestinal permeability increase using dead bacteria and acetic acid.
Documented Applications
Prevention or treatment of small intestinal injury in a human or a non-human animal induced by NSAIDs with half-life less than 14 hours in combination with proton pump inhibitors.
Prevention or treatment of fat-associated disease and/or inflammation accompanying such small intestinal injury, including NAFLD/NASH associated with endotoxin-mediated permeability.
Interested in licensing this patent?